Skip to main content

Press Releases

Press Release RSS Feed (opens in new window)
Press release year list 2019 2018 2017 2016
08/21/2019
Tetra Bio-Pharma Announces Joint Venture with Thorne and Onegevity Health to Form CB2 Therapeutics
08/12/2019
Tetra Bio-Pharma Engages LifeSci Advisors and LifeSci Public Relations as Strategic Partners
08/02/2019
Tetra's Officers and Employees Participate in Private Placement
07/30/2019
Tetra's Officers and Employees Participate in Private Placement
07/18/2019
Tetra Bio-Pharma’s Management Post Financing Corporate Update
Download PDF format download (opens in new window)
07/12/2019
Tetra Bio-Pharma Announces Closing of Unit Offering
07/11/2019
Panag Pharma Receives a Repayable $500,000 Contribution from the Atlantic Canada Opportunities Agency (ACOA)
07/05/2019
Tetra Bio-Pharma Comments on Recent Trading Activity at the Request of IIROC
06/24/2019
Tetra Bio-Pharma Inc. Announces Pricing of Unit Offering
06/21/2019
Tetra Bio-Pharma Inc. Announces Voting Results of 2019 Annual General and Special Meeting
06/19/2019
Tetra Bio-Pharma Inc. Announces Proposed Offering of Units
06/18/2019
Tetra Bio-Pharma’s Management Provides Corporate Update Ahead of Annual General Meeting
06/17/2019
Tetra Bio-Pharma Inc. Announces Change of Annual General Meeting Time
06/17/2019
Tetra Bio-Pharma Announces PPP003 Program Update Following Type B Meeting With U.S. FDA
06/14/2019
Tetra Bio-Pharma Inc. Announces Director Resignation
06/11/2019
Panag Pharma Completes Phase 3 Trial With Awaye™
05/30/2019
Tetra Bio-Pharma to Present Key Research Findings as Part of Food and Drug Administration (FDA) Public Hearing on CBD
05/14/2019
Tetra Bio-Pharma Announces the Retirement of Bernard Lessard and the Appointment of Sabino Di Paola as Chief Financial Officer
05/09/2019
Tetra Bio-Pharma’s Recently acquired Wholly Owned Subsidiary Panag Pharma Provides an Update on Recent Activities
05/02/2019
Tetra Bio-Pharma’s Subsidiary, Panag Pharma, Obtains Health Canada Authorization to Commence Its First Veterinary Clinical Study
05/01/2019
Tetra Bio-Pharma Closes the Acquisition of Panag Pharma
04/29/2019
Tetra Bio-Pharma and Altus Formulation Sign Joint Venture Agreement for Cannabinoid Drug Product Development
04/18/2019
Tetra Bio-Pharma Shareholders Approve the Acquisition of Panag Pharma
04/11/2019
Tetra Bio-Pharma and Ovensa Will Engage in a Collaboration to Tackle Brain Cancer
04/09/2019
Tetra Bio-Pharma Resumes its Phase 3 Clinical Trial Program
04/01/2019
Tetra Bio-Pharma Announces Employment Contract Renewal of CEO Guy Chamberland
03/27/2019
Tetra Bio-Pharma to File PPP001 With the European Medicines Agency
03/06/2019
Tetra Bio-Pharma Names Vice-President, Clinical Programs and Medical Affairs to Its Leadership Team
03/04/2019
Tetra Bio-Pharma and Santé Cannabis Announce Completion of the First Phase 2 Cannabis Oil Trial in Cancer and Non-Cancer Patients
02/26/2019
Two in Three (65%) Canadians Would Take a Drug Containing Cannabis if Prescribed by a Doctor and Covered by Insurance
02/12/2019
Tetra Bio-Pharma Provides Update on its Neuropathic and Chronic Pain Drug Development Program
02/08/2019
Tetra Bio-Pharma Announces Stock Option Grants
02/07/2019
Tetra Bio-Pharma Pursues Its Research Priorities Accelerating Other Drug Development Plans
02/05/2019
Tetra Bio-Pharma Redefines Quality Standards for Pharmaceutical Grade Cannabis-Derived Products
02/04/2019
Crescita Therapeutics Inc.™ and Tetra Natural Health Collaborate to Enhance Transdermal Delivery of Beta-Caryophyllene in Tetra’s Dermatology Product Portfolio
01/30/2019
Tetra Bio-Pharma Enters into Definitive Agreement to Acquire Panag Pharma Inc.
Download PDF format download (opens in new window)
01/28/2019
Tetra Bio-Pharma Files Patent Application to Protect PPP001
01/14/2019
Tetra Natural Health Adds New Leaders to its Commercial Operations